^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

16P - Understanding the biologic determinants of ribociclib efficacy in breast cancer

Published date:
05/03/2021
Excerpt:
Here, we performed gene expression (GE) analysis with/without ribociclib monotherapy in BC patient-derived xenografts (PDX)…PDXs showed a statistically significant higher response to ribociclib (mean change in volume >40% and >140%), than B-L (>660%). Baseline GE analysis identified 6 genes highly expressed in responders (FOXA1, ERBB2, GRB7, MLPH, GPR160 and CXXC5), and 7 lower expressed genes (SFRP1, KRT17, MYC, CDH3, KRT5, MIA and KRT14).